APR 1 6 2004

K033447
page 1 of 2

510(k) Summary
Linvatec Biomaterials
Cannulated NuGen™ FX Screw

Submitter's Name, Address, Telephone Number, and Contact Person

Linvatec Biomaterials Ltd.
Tuija Annala
Director, Quality and Regulatory Affairs
P.O.Box 3
FIN-33721 Tampere
Finland, Europe
Phone: 358-3-316 5600
Facsimile: 358-3-316 5629

Date prepared: July 29, 2003

Name of the device:

A.	Trade or Proprietary Name:	Cannulated NuGen™ FX Screw
B.	Common Name:	Bioabsorbable, Threaded, Fixation Rod
C.	Classification Name:	Biodegradable fixation fastener, bone
D.	Device Product Code:	HWC

Predicate Devices:

Bionx Implants Inc. Biofix® Bioabsorbable SR-PLLA Threaded Fixation Rod (K952471)
Bionx Implants Inc. Biofix® Bioabsorbable, Threaded, Distal Radius Screw (K974876, K992947)
Bionx Implants Inc. SmartScrew™ (K003077)
Bionx Implants Inc. SmartScrew™ (K012001)
Bionx Implants Inc. NuGen™ FX Screw (K023022)

Intended Use:

Cannulated NuGen™ FX Screw is generally intended for maintenance of alignment and fixation of fractures, osteotomies, arthrodeses or condylar grafts within the condylar aspects of the upper extremity, ankle and foot, in the presence of appropriate brace and/or immobilization. Specifically, it is intended for phalangeal fusion and fracture, metacarpal fusion and fracture, carpal fusion and fracture, wrist arthrodesis, Distal radius fractures, olecranon fractures, radial head fractures, humeral condylar fractures, cancellous fractures and osteotomies of the malleolus, ankle fractures, metatarsal osteotomies and correction of hallux valgus.

K03>447
page 2 of 2

The NuGen™ FX Screw is not intended for use in and is contraindicated for: 1) Fractures and osteotomies of cortical bone (except those in the hand and foot) and proximal femoral fractures. 2) Situations where internal fixation is otherwise contraindicated, e.g.. active or potential infection and where patient co-operation cannot be guaranteed (e.g. alcoholism). 3) Highly comminuted fractures, which would not be appropriate for fixation with metallic screws. 4) Patients with suspected or known allergy to the implant material.

Device Description:

The device description of the Cannulated NuGen™ FX Screw biodegradable bone fixation screw is as follows.

- Composed of poly-L/D-lactide copolymer
- Lengths 14 - 70mm
- Diameters 3.5mm with cannulation for 1.2mm K-wire and 4.5 mm with cannulation for 1.6mm K-wire.
- Fully and partly threaded models

The only modifications that were made are:

- Amendment of screw models with cannulation
- Amendment of suitable instruments into instrumentation accordingly.

Substantial Equivalence:

The Cannulated NuGen FX Screw™ has the following similarities to the cleared models of NuGen FX Screw (K012001, K023022):

- has the same indicated use
- uses the same operating principle
- incorporates the same basic design of thread
- utilizes the same basic dimensions
- is manufactured by machining
- is packaged and sterilized using the same materials and processes
- has the same shelf life

In summary, the Cannulated NuGen™ FX Screw described in this notification is, in our opinion, substantially equivalent to the predicate device. Furthermore, the minor technological differences between the NuGen™ FX Screw and the predicate devices do not raise any new issues of safety or effectiveness.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

APR 1 6 2004

Ms. Tuija Annala
Director, Quality and Regulatory Affairs
Linvatec Biomaterials Ltd.
Hermiankatu 6-8 L
FIN 33721
Tampere, Finland

Re: K032447
Trade/Device Name: Cannulated NuGen™ FX Screw
Regulation Number: 21 CFR 888.3040
Regulation Name: Smooth or threaded metallic bone fixation fastener
Regulatory Class: II
Product Code: HWC
Dated: March 24, 2004
Received: March 29, 2004

Dear Ms. Annala:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

for Mark N. Melkerson

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE

510(K) Number (if known): K032447

Device Name: Cannulated NuGen™ FX Screw

Indications for Use:

The Cannulated NuGen™ FX Screw is generally intended for maintenance of alignment and fixation of fractures, osteotomies, arthrodeses or condylar grafts within the condylar aspects of the upper extremity, ankle and foot, in the presence of appropriate brace and/or immobilization. Specifically, it is intended for phalangeal fusion and fracture, metacarpal fusion and fracture, carpal fusion and fracture, wrist arthrodesis, Distal radius fractures, olecranon fractures, radial head fractures, humeral condylar fractures, cancellous fractures and osteotomies of the malleolus, ankle fractures, metatarsal osteotomies and correction of hallux valgus.

The Cannulated NuGen™ FX Screw is not intended for use in and is contraindicated for: 1) Fractures and osteotomies of cortical bone (except those in the hand and foot) and proximal femoral fractures. 2) Situations where internal fixation is otherwise contraindicated, e.g.. active or potential infection and where patient co-operation cannot be guaranteed (e.g. alcoholism). 3) Highly comminuted fractures, which would not be appropriate for fixation with metallic screws. 4) Patients with suspected or known allergy to the implant material.

Please do not write below this line – continue on another page is needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use No

(Per 21 CFR 801.109)

for Mark N Melkerson

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number K032447